SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jay silberman who wrote (1991)10/2/1997 6:50:00 AM
From: Henry Niman   of 6136
 
jay, I think that the Lehman report is in error when it indicates that the AGPH study is not consistant with the Torres study on resistance in patients who have had prior therapy but are naive to PIs:
"Torres
presented an analysis of serum viral load in patients previously naive to PI
therapy who, following resistance to drug treatment that included Viracept,
nelfinavir, went on to other PIs. In 8 patients observed who failed the drug,
subsequent treatment with either Saquinavir or Indinavir resulted in only 25%
of patients being sensitive to the second PI. One might conclude that the
resistance profile of Nelfinavir is not sufficiently unique to allow broad
susceptibility the subsequent PI therapy. Without accompanying genotypic
data, though, it is our view that the study's conclusion may be aggressive.
Moreover, these data do not appear to be consistent with those of Henry, et
al. (St. Paul Medical Center) that will be presented on Wednesday which
predicts in 9 patients that failed Nelfinavir allows susceptibility to
treatment with a cocktail involving other PIs (Saquinavir and Indinavir)."

The failure of 75% (6 of 8) of patients who had prior therapy, but no PI in the Torres study with the 57% (4 of 7) who failed in the AGPH study are really not that different. Since the numbers were small and the prior treatment history of both groups is probably heterogeneous, the two results actually confirm rather than contradict each other (the 4 of 7 comes from the AGPH press release, I'm not sure where the 9 in the Lehman reiterated BUY comes from).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News